Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rodney Baber AM

Prof Rodney Baber AM

MHT For Women With History or Risk of Cancer

Dr Chris Bollen

Dr Chris Bollen

Muscle Health in the Elderly

Prof Brendon Yee

Prof Brendon Yee

GLP-1s For OSA

Dr Andrew Scroop

Dr Andrew Scroop

Oral Corticosteroid Stewardship For Asthma – Why it is Important

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Martin MacDonald

expert

Dr Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Date published: 20 November 2023